An open-label Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Myelodysplastic Syndrome, Unspecified
  • Age: Between 18 - 75 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. A confirmed relapsed or refractory acute myeloid leukemia (AML) OR 2. A confirmed high risk myelodysplastic syndrome (MDS)

You may not be eligible for this study if the following are true:

  • 1. The patient has a confirmed or suspected tumor involvement in the central nervous system (CNS). 2. Patients who have received any cancer therapy (Investigational agent or not), including but not limited to chemotherapy, small molecules, monoclonal antibodies (e.g., immune checkpoint blockade therapies), or radiotherapy within 2 weeks. 3. Patient is under systemic immunosuppressive drugs
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.